
Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud
WASHINGTON, D.C., May 01, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ: ZBIO) entered the public markets in September 2024 with a $17 per share debut and bold projections. But within weeks, investors were facing a much different picture—one that …